Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes
Infection Control & Hospital Epidemiology · 2024
DOI: 10.1017/ice.2024.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection Control & Hospital Epidemiology, 2024. Verfasst von Sarah M Bartsch und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Technology and Communication in Health (CATCH), CUNY Graduate School of Public Health and Health Policy, New York City, New York. Hauptthemen laut MEDLINE: Nursing Homes, Cost-Benefit Analysis, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, AHRQ HHS, NCATS NIH HHS.
Themen: Langzeitpflege
Abstract (Originalsprache)
Objective
Nursing home residents may be particularly vulnerable to coronavirus disease 2019 (COVID-19). Therefore, a question is when and how often nursing homes should test staff for COVID-19 and how this may change as severe acute respiratory coronavirus virus 2 (SARS-CoV-2) evolves.
Design
We developed an agent-based model representing a typical nursing home, COVID-19 spread, and its health and economic outcomes to determine the clinical and economic value of various screening and isolation strategies and how it may change under various circumstances.
Results
Under winter 2023–2024 SARS-CoV-2 omicron variant conditions, symptom-based antigen testing averted 4.5 COVID-19 cases compared to no testing, saving $191 in direct medical costs. Testing implementation costs far outweighed these savings, resulting in net costs of $990 from the Centers for Medicare & Medicaid Services perspective, $1,545 from the third-party payer perspective, and $57,155 from the societal perspective. Testing did not return sufficient positive health effects to make it cost-effective [$50,000 per quality-adjusted life-year (QALY) threshold], but it exceeded this threshold in ≥59% of simulation trials. Testing remained cost-ineffective when routinely testing staff and varying face mask compliance, vaccine efficacy, and booster coverage. However, all antigen testing strategies became cost-effective (≤$31,906 per QALY) or cost saving (saving ≤$18,372) when the severe outcome risk was ≥3 times higher than that of current omicron variants.
Conclusions
SARS-CoV-2 testing costs outweighed benefits under winter 2023–2024 conditions; however, testing became cost-effective with increasingly severe clinical outcomes. Cost-effectiveness can change as the epidemic evolves because it depends on clinical severity and other intervention use. Thus, nursing home administrators and policy makers should monitor and evaluate viral virulence and other interventions over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Advanced Technology and Communication in Health (CATCH), CUNY Graduate School of Public Health and Health Policy, New York City, New York.
- Public Health Informatics, Computational, and Operations Research (PHICOR), CUNY Graduate School of Public Health and Health Policy, New York City, New York.
- Artificial Intelligence, Modeling, and Informatics, for Nutrition Guidance and Systems (AIMINGS) Center, CUNY Graduate School of Public Health and Health Policy, New York City, New York.
- Los Angeles Jewish Home, Reseda, California.
- California Association of Long Term Care Medicine, Santa Clarita, California.
- Division of Infectious Diseases, University of California Irvine School of Medicine, Irvine, California.
ORCID-Profile: Colleen Weatherwax, Jessie L Heneghan, Gabrielle M Gussin, Sheryl A Scannell, Susan S Huang, Bruce Y Lee
Förderung
- NIGMS NIH HHS
- AHRQ HHS
- NCATS NIH HHS
Zitieren
APA
Bartsch, S. M., Weatherwax, C., Martinez, M. F., Chin, K. L., Wasserman, M. R., Singh, R. D., Heneghan, J. L., Gussin, G. M., Scannell, S. A., White, C., Leff, B., Huang, S. S., & Lee, B. Y. (2024). Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes. Infection Control & Hospital Epidemiology. https://doi.org/10.1017/ice.2024.9
Vancouver
Bartsch SM, Weatherwax C, Martinez MF, Chin KL, Wasserman MR, Singh RD, et al. Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes. Infection Control & Hospital Epidemiology. 2024. doi:10.1017/ice.2024.9
BibTeX
@article{Bartsch2024,
author = {Bartsch, Sarah M and Weatherwax, Colleen and Martinez, Marie F and Chin, Kevin L and Wasserman, Michael R and Singh, Raveena D and Heneghan, Jessie L and Gussin, Gabrielle M and Scannell, Sheryl A and White, Cameron and Leff, Bruce and Huang, Susan S and Lee, Bruce Y},
title = {Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes},
journal = {Infection Control & Hospital Epidemiology},
year = {2024},
doi = {10.1017/ice.2024.9}
}
EUVIMED